Бролуцизумаб (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Бролуцизумаб" in Serbian language version.

refsWebsite

Global rank Serbian rank

16nih.gov

4^th place

8^th place

15doi.org

2^nd place

4^th place

4archive.org

6^th place

5^th place

3semanticscholar.org

11^th place

23^rd place

3medscape.com

719^th place

468^th place

3fda.gov

447^th place

925^th place

2clinicaltrials.gov

5,225^th place

6,444^th place

2europa.eu

68^th place

107^th place

1tga.gov.au

3,984^th place

low place

1canada.ca

1,712^th place

6,766^th place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

low place

1novartis.com

low place

9,999^th place

1reuters.com

49^th place

103^rd place

archive.org

Bhisitkul, R. B. (2006). „Vascular endothelial growth factor biology: Clinical implications for ocular treatments”. British Journal of Ophthalmology. 90 (12): 1542—1547. PMC 1857529 . PMID 17114590. doi:10.1136/bjo.2006.098426.
Zhang, H-T; Scott, P A E.; Morbidelli, L.; Peak, S.; Moore, J.; Turley, H.; Harris, A. L.; Ziche, M.; Bicknell, R. (2000). „The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo”. British Journal of Cancer. 83 (1): 63—68. PMC 2374542 . PMID 10883669. doi:10.1054/bjoc.2000.1279.
Ng, Eugene W.M.; Adamis, Anthony P. (2005). „Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration”. Canadian Journal of Ophthalmology. 40 (3): 352—368. PMID 15947805. doi:10.1016/S0008-4182(05)80078-X.
Kvanta, A.; Algvere, P. V.; Berglin, L.; Seregard, S. (1996). „Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor”. Invest Ophthalmol Vis Sci. 37 (9): 1929—1934. PMID 8759365.

canada.ca

health-products.canada.ca

„Beovu Product information”. Health Canada. 25. 4. 2012. Приступљено 29. 5. 2022.

clinicaltrials.gov

„Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 (HAWK)”. ClinicalTrials.gov. 4. 12. 2014. Приступљено 3. 5. 2020.
„Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (HARRIER)”. ClinicalTrials.gov. 5. 5. 2015. Приступљено 3. 5. 2020.

doi.org

Tadayoni, R.; Sararols, L.; Weissgerber, G.; Verma, R.; Clemens, A.; Holz, F. G. (2021). „Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration”. Ophthalmologica. 244 (2): 93—101. PMID 33197916. S2CID 226989098. doi:10.1159/000513048. .
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG (април 2019). „HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration”. Ophthalmology. 127 (1): 72—84. PMID 30986442. doi:10.1016/j.ophtha.2019.04.017 .
Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, Larsen M, Weichselberger A, Wenzel A, Schmidt A, Escher D, Sararols L, Souied E (мај 2016). „Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study”. Ophthalmology. 123 (5): 1080—9. PMID 26906165. doi:10.1016/j.ophtha.2015.12.030 .
Pasqualetti, Giuseppe; Danesi, Romano; Del Tacca, Mario; Bocci, Guido (2007). „Vascular endothelial growth factor pharmacogenetics: A new perspective for anti-angiogenic therapy”. Pharmacogenomics. 8 (1): 49—66. PMID 17187509. doi:10.2217/14622416.8.1.49.
Takahashi, Hiroyuki; Shibuya, Masabumi (2005). „The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions”. Clinical Science. 109 (3): 227—241. PMID 16104843. doi:10.1042/CS20040370.
Bhisitkul, R. B. (2006). „Vascular endothelial growth factor biology: Clinical implications for ocular treatments”. British Journal of Ophthalmology. 90 (12): 1542—1547. PMC 1857529 . PMID 17114590. doi:10.1136/bjo.2006.098426.
Keyt, Bruce A.; Berleau, Lea T.; Nguyen, Hung V.; Chen, Helen; Heinsohn, Henry; Vandlen, Richard; Ferrara, Napoleone (1996). „The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor is Critical for itItsitogenic Potency”. Journal of Biological Chemistry. 271 (13): 7788—7795. PMID 8631822. doi:10.1074/jbc.271.13.7788 .
Zhang, H-T; Scott, P A E.; Morbidelli, L.; Peak, S.; Moore, J.; Turley, H.; Harris, A. L.; Ziche, M.; Bicknell, R. (2000). „The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo”. British Journal of Cancer. 83 (1): 63—68. PMC 2374542 . PMID 10883669. doi:10.1054/bjoc.2000.1279.
Ng, Eugene W.M.; Adamis, Anthony P. (2005). „Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration”. Canadian Journal of Ophthalmology. 40 (3): 352—368. PMID 15947805. doi:10.1016/S0008-4182(05)80078-X.
Deng, Yong; Zhang, Xi; Simons, Michael (2015). „Molecular Controls of Lymphatic VEGFR3 Signaling”. Arteriosclerosis, Thrombosis, and Vascular Biology. 35 (2): 421—429. PMC 4304921 . PMID 25524775. doi:10.1161/ATVBAHA.114.304881.
Rakic, Jean-Marie; Lambert, Vincent; Devy, Laetitia; Luttun, Aernout; Carmeliet, Peter; Claes, Carel; Nguyen, Laurent; Foidart, Jean-Michel; Noe¨l, Agne's; Munaut, Carine (2003). „Placental Growth Factor, a Member of the VEGF Family, Contributes to the Development of Choroidal Neovascularization”. Investigative Opthalmology & Visual Science. 44 (7): 3186—3193. PMID 12824270. doi:10.1167/iovs.02-1092.
Aiello, Lloyd Paul; Avery, Robert L.; Arrigg, Paul G.; Keyt, Bruce A.; Jampel, Henry D.; Shah, Sabera T.; Pasquale, Louis R.; Thieme, Hagen; Iwamoto, Mami A.; Park, John E.; Nguyen, Hung V.; Aiello, Lloyd M.; Ferrara, Napoleone; King, George L. (1994). „Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders”. New England Journal of Medicine. 331 (22): 1480—1487. PMID 7526212. doi:10.1056/NEJM199412013312203.
Frank, Robert N. (1997). „Growth Factors in Age-Related Macular Degeneration: Pathogenic and Therapeutic Implications”. Ophthalmic Research. 29 (5): 341—353. PMID 9323725. doi:10.1159/000268032.
Szabó, E.; Phillips, D. J.; Droste, M.; Marti, A.; Kretzschmar, T.; Shamshiev, A.; Weller, M. (2018). „Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models”. J Pharmacol Exp Ther. 365 (2): 422—429. PMID 29507055. S2CID 3738110. doi:10.1124/jpet.117.246249.
Szabó, Emese; Phillips, Douglas J.; Droste, Miriam; Marti, Andrea; Kretzschmar, Titus; Shamshiev, Abdijapar; Weller, Michael (2018). „Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models”. Journal of Pharmacology and Experimental Therapeutics. 365 (2): 422—429. PMID 29507055. S2CID 3738110. doi:10.1124/jpet.117.246249.

europa.eu

ema.europa.eu

EMA (2019-12-10). „Beovu”. European Medicines Agency (на језику: енглески). Приступљено 2023-06-24.
EMA (2019-12-10). „Beovu”. European Medicines Agency (на језику: енглески). Приступљено 2023-06-23.

fda.gov

accessdata.fda.gov

„Drug Approval Package: BEOVU (brolucizumab-dbll)”. www.accessdata.fda.gov (на језику: енглески). Приступљено 2023-06-24.
Drug Approval Package: BEOVU (brolucizumab-dbll). Accessed July 24, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761125_Orig1_toc.cfm

fda.gov

Research, Center for Drug Evaluation and (2020-01-27). „Drug Trials Snapshots: BEOVU”. FDA (на језику: енглески).

hres.ca

hpr-rps.hres.ca

„Summary Basis of Decision (SBD) for Beovu”. Health Canada. 23. 10. 2014. Приступљено 29. 5. 2022.

medicines.org.uk

„Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)”. (emc). 9. 3. 2020. Приступљено 3. 5. 2020.

medscape.com

reference.medscape.com

„Pharmacology In: Beovu (brolucizumab intravitreal) dosing, indications, interactions, adverse effects, and more”. reference.medscape.com. Приступљено 2023-06-25.
„Pregnancy & Lactation У: Beovu (brolucizumab intravitreal) dosing, indications, interactions, adverse effects, and more”. reference.medscape.com. Приступљено 2023-06-25.
„Beovu (brolucizumab intravitreal) dosing, indications, interactions, adverse effects, and more”. reference.medscape.com. Приступљено 2023-06-24.

nih.gov

ncbi.nlm.nih.gov

Tadayoni, R.; Sararols, L.; Weissgerber, G.; Verma, R.; Clemens, A.; Holz, F. G. (2021). „Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration”. Ophthalmologica. 244 (2): 93—101. PMID 33197916. S2CID 226989098. doi:10.1159/000513048. .
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG (април 2019). „HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration”. Ophthalmology. 127 (1): 72—84. PMID 30986442. doi:10.1016/j.ophtha.2019.04.017 .
Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, Larsen M, Weichselberger A, Wenzel A, Schmidt A, Escher D, Sararols L, Souied E (мај 2016). „Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study”. Ophthalmology. 123 (5): 1080—9. PMID 26906165. doi:10.1016/j.ophtha.2015.12.030 .
Pasqualetti, Giuseppe; Danesi, Romano; Del Tacca, Mario; Bocci, Guido (2007). „Vascular endothelial growth factor pharmacogenetics: A new perspective for anti-angiogenic therapy”. Pharmacogenomics. 8 (1): 49—66. PMID 17187509. doi:10.2217/14622416.8.1.49.
Takahashi, Hiroyuki; Shibuya, Masabumi (2005). „The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions”. Clinical Science. 109 (3): 227—241. PMID 16104843. doi:10.1042/CS20040370.
Bhisitkul, R. B. (2006). „Vascular endothelial growth factor biology: Clinical implications for ocular treatments”. British Journal of Ophthalmology. 90 (12): 1542—1547. PMC 1857529 . PMID 17114590. doi:10.1136/bjo.2006.098426.
Keyt, Bruce A.; Berleau, Lea T.; Nguyen, Hung V.; Chen, Helen; Heinsohn, Henry; Vandlen, Richard; Ferrara, Napoleone (1996). „The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor is Critical for itItsitogenic Potency”. Journal of Biological Chemistry. 271 (13): 7788—7795. PMID 8631822. doi:10.1074/jbc.271.13.7788 .
Zhang, H-T; Scott, P A E.; Morbidelli, L.; Peak, S.; Moore, J.; Turley, H.; Harris, A. L.; Ziche, M.; Bicknell, R. (2000). „The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo”. British Journal of Cancer. 83 (1): 63—68. PMC 2374542 . PMID 10883669. doi:10.1054/bjoc.2000.1279.
Ng, Eugene W.M.; Adamis, Anthony P. (2005). „Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration”. Canadian Journal of Ophthalmology. 40 (3): 352—368. PMID 15947805. doi:10.1016/S0008-4182(05)80078-X.
Deng, Yong; Zhang, Xi; Simons, Michael (2015). „Molecular Controls of Lymphatic VEGFR3 Signaling”. Arteriosclerosis, Thrombosis, and Vascular Biology. 35 (2): 421—429. PMC 4304921 . PMID 25524775. doi:10.1161/ATVBAHA.114.304881.
Rakic, Jean-Marie; Lambert, Vincent; Devy, Laetitia; Luttun, Aernout; Carmeliet, Peter; Claes, Carel; Nguyen, Laurent; Foidart, Jean-Michel; Noe¨l, Agne's; Munaut, Carine (2003). „Placental Growth Factor, a Member of the VEGF Family, Contributes to the Development of Choroidal Neovascularization”. Investigative Opthalmology & Visual Science. 44 (7): 3186—3193. PMID 12824270. doi:10.1167/iovs.02-1092.
Aiello, Lloyd Paul; Avery, Robert L.; Arrigg, Paul G.; Keyt, Bruce A.; Jampel, Henry D.; Shah, Sabera T.; Pasquale, Louis R.; Thieme, Hagen; Iwamoto, Mami A.; Park, John E.; Nguyen, Hung V.; Aiello, Lloyd M.; Ferrara, Napoleone; King, George L. (1994). „Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders”. New England Journal of Medicine. 331 (22): 1480—1487. PMID 7526212. doi:10.1056/NEJM199412013312203.
Kvanta, A.; Algvere, P. V.; Berglin, L.; Seregard, S. (1996). „Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor”. Invest Ophthalmol Vis Sci. 37 (9): 1929—1934. PMID 8759365.
Frank, Robert N. (1997). „Growth Factors in Age-Related Macular Degeneration: Pathogenic and Therapeutic Implications”. Ophthalmic Research. 29 (5): 341—353. PMID 9323725. doi:10.1159/000268032.
Szabó, E.; Phillips, D. J.; Droste, M.; Marti, A.; Kretzschmar, T.; Shamshiev, A.; Weller, M. (2018). „Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models”. J Pharmacol Exp Ther. 365 (2): 422—429. PMID 29507055. S2CID 3738110. doi:10.1124/jpet.117.246249.
Szabó, Emese; Phillips, Douglas J.; Droste, Miriam; Marti, Andrea; Kretzschmar, Titus; Shamshiev, Abdijapar; Weller, Michael (2018). „Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models”. Journal of Pharmacology and Experimental Therapeutics. 365 (2): 422—429. PMID 29507055. S2CID 3738110. doi:10.1124/jpet.117.246249.

novartis.com

„Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept”. Novartis (на језику: енглески). Приступљено 2023-06-24.

reuters.com

BRIEF-U.S. FDA Approves Novartis’ Updated Beovu Label - Statement. Reuters. https://www.reuters.com/article/brief-us-fda-approves-novartis-updated-b-idINASN0007VL Published June 11, 2020. Accessed July 24, 2021.

semanticscholar.org

api.semanticscholar.org

Tadayoni, R.; Sararols, L.; Weissgerber, G.; Verma, R.; Clemens, A.; Holz, F. G. (2021). „Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration”. Ophthalmologica. 244 (2): 93—101. PMID 33197916. S2CID 226989098. doi:10.1159/000513048. .
Szabó, E.; Phillips, D. J.; Droste, M.; Marti, A.; Kretzschmar, T.; Shamshiev, A.; Weller, M. (2018). „Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models”. J Pharmacol Exp Ther. 365 (2): 422—429. PMID 29507055. S2CID 3738110. doi:10.1124/jpet.117.246249.
Szabó, Emese; Phillips, Douglas J.; Droste, Miriam; Marti, Andrea; Kretzschmar, Titus; Shamshiev, Abdijapar; Weller, Michael (2018). „Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models”. Journal of Pharmacology and Experimental Therapeutics. 365 (2): 422—429. PMID 29507055. S2CID 3738110. doi:10.1124/jpet.117.246249.

tga.gov.au

Medicine registrations Australian Government